302 related articles for article (PubMed ID: 19665589)
1. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?
Ruzzene M; Pinna LA
Biochim Biophys Acta; 2010 Mar; 1804(3):499-504. PubMed ID: 19665589
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase CK2 as a druggable target.
Sarno S; Pinna LA
Mol Biosyst; 2008 Sep; 4(9):889-94. PubMed ID: 18704226
[TBL] [Abstract][Full Text] [Related]
3. Assessment of CK2 constitutive activity in cancer cells.
Ruzzene M; Di Maira G; Tosoni K; Pinna LA
Methods Enzymol; 2010; 484():495-514. PubMed ID: 21036247
[TBL] [Abstract][Full Text] [Related]
4. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase CK2 inhibition as a pharmacological strategy.
Borgo C; Ruzzene M
Adv Protein Chem Struct Biol; 2021; 124():23-46. PubMed ID: 33632467
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?
Bortolato A; Cozza G; Moro S
Anticancer Agents Med Chem; 2008 Oct; 8(7):798-806. PubMed ID: 18855581
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase CK2 accumulation in "oncophilic" cells: causes and effects.
Ruzzene M; Tosoni K; Zanin S; Cesaro L; Pinna LA
Mol Cell Biochem; 2011 Oct; 356(1-2):5-10. PubMed ID: 21735095
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells.
Franchin C; Cesaro L; Salvi M; Millioni R; Iori E; Cifani P; James P; Arrigoni G; Pinna L
Biochim Biophys Acta; 2015 Jun; 1854(6):609-23. PubMed ID: 25278378
[TBL] [Abstract][Full Text] [Related]
9. Casein Kinase II: an attractive target for anti-cancer drug design.
Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
[TBL] [Abstract][Full Text] [Related]
10. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
11. Emergence of protein kinase CK2 as a key target in cancer therapy.
Trembley JH; Chen Z; Unger G; Slaton J; Kren BT; Van Waes C; Ahmed K
Biofactors; 2010; 36(3):187-95. PubMed ID: 20533398
[TBL] [Abstract][Full Text] [Related]
12. Generation and quantitative proteomics analysis of CK2α/α'
Borgo C; Franchin C; Scalco S; Bosello-Travain V; Donella-Deana A; Arrigoni G; Salvi M; Pinna LA
Sci Rep; 2017 Feb; 7():42409. PubMed ID: 28209983
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase CK2: a newcomer in the 'druggable kinome'.
Pagano MA; Cesaro L; Meggio F; Pinna LA
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1303-6. PubMed ID: 17073807
[TBL] [Abstract][Full Text] [Related]
14. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
15. Contribution of the CK2 Catalytic Isoforms α and α' to the Glycolytic Phenotype of Tumor Cells.
Zonta F; Borgo C; Quezada Meza CP; Masgras I; Rasola A; Salvi M; Pinna LA; Ruzzene M
Cells; 2021 Jan; 10(1):. PubMed ID: 33477590
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
17. Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.
Zanin S; Borgo C; Girardi C; O'Brien SE; Miyata Y; Pinna LA; Donella-Deana A; Ruzzene M
PLoS One; 2012; 7(11):e49193. PubMed ID: 23145120
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.
Di Maira G; Brustolon F; Bertacchini J; Tosoni K; Marmiroli S; Pinna LA; Ruzzene M
Oncogene; 2007 Oct; 26(48):6915-26. PubMed ID: 17486073
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase CK2 and angiogenesis.
Montenarh M
Adv Clin Exp Med; 2014; 23(2):153-8. PubMed ID: 24913104
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase CK2 phosphorylates and upregulates Akt/PKB.
Di Maira G; Salvi M; Arrigoni G; Marin O; Sarno S; Brustolon F; Pinna LA; Ruzzene M
Cell Death Differ; 2005 Jun; 12(6):668-77. PubMed ID: 15818404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
